Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Incyte Appointments Dave Gardner, EVP & Chief Strategy Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Incyte Appointments Dave Gardner, EVP & Chief Strategy Officer

Gardner joins with over 20 years of experience in pharmaceutical and biotechnology investing and advising.

By: Rachel Klemovitch

Assistant Editor

Incyte named Dave Gardner Executive Vice President and Chief Strategy Officer (CSO) effective September 22, 2025. In his new role, Gardner will serve as a key member of the Executive Leadership Team and be responsible for the company’s strategy and business development.

After nine years as a key member of the Incyte leadership team, Vijay Iyengar, M.D., Executive Vice President and Head of Global Medical Affairs and Product and Partnership Strategy, will be retiring from Incyte and will continue to provide transitional support to Gardner through the end of the year.

Gardner has over 20 years of experience in pharmaceutical and biotechnology investing and advising. He most recently served as Partner on the Therapeutics Team at Rock Springs Capital Management, leading strategy across Oncology, Neurology, Immunology, and Rare Diseases. Before that, Gardner spent a decade at BlackRock as Vice President and Equity Research Analyst, where he was responsible for the Health Care sector. 

“Dave possesses a unique combination of business acumen, scientific knowledge, and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development,” said Bill Meury, President and CEO, Incyte. “Dave will play a pivotal role in developing a coherent and executable long-term growth strategy for the company and ensuring our portfolio decisions, business development, and strategic partnerships position Incyte for sustainable value creation.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters